<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MORPHINE SULFATE <img border="0" src="../images/pr.gif"/></span><br/>(mor'feen)<br/><span class="topboxtradename">Astramorph PF, </span><span class="topboxtradename">Avinza, </span><span class="topboxtradename">DepoDur, </span><span class="topboxtradename">Duramorph, </span><span class="topboxtradename">Epimorph <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Kadian, </span><span class="topboxtradename">MSIR, </span><span class="topboxtradename">MS Contin, </span><span class="topboxtradename">Oramorph SR, </span><span class="topboxtradename">Roxanol, </span><span class="topboxtradename">RMS, </span><span class="topboxtradename">Statex <img border="0" src="../images/maple.gif"/><br/></span><b>Classifications:</b> <span class="classification">central nervous system (cns) agent</span>; <span class="classification">analgesic</span>; <span class="classification">narcotic (opiate) agonist</span><br/><b>Pregnancy Category: </b>B  (D in long-term use or high dose)<br/><b>Controlled Substance: </b>Schedule II<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg, 15 mg, 30 mg tablets/capsules; 15 mg, 20 mg, 30 mg, 60 mg, 100 mg, 120 mg, 200 mg controlled release tablets/capsules; 10 mg/2.5 mL, 10 mg/5 ml, 20 mg/mL, 20 mg/5 mL, 30 mg/1.5 mL, 100 mg/5 mL oral solution; 0.5 mg/mL, 1 mg/mL, 2 mg/mL, 4 mg/mL, 5 mg/mL, 8 mg/mL, 10 mg/mL, 15 mg/mL, 25 mg/mL, 50 mg/mL injection; 10 mg/mL, 15 mg/1.5 mL, 20 mg/2 mL extended-release lysosomal injection; 5 mg, 10 mg, 20 mg, 30 mg suppositories</p>
<h1><a name="action">Actions</a></h1>
<p>Natural opium alkaloid with agonist activity by binding with the same receptors as endogenous opioid peptides. Narcotic agonist
         effects are identified with 3 types of receptors: Analgesia at supraspinal level, euphoria, respiratory depression and physical
         dependence; analgesia at spinal level, sedation and miosis; and dysphoric, hallucinogenic and cardiac stimulant effects.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Controls severe pain; also used as an adjunct to anesthesia.</p>
<h1><a name="uses">Uses</a></h1>
<p>Symptomatic relief of severe acute and chronic pain after nonnarcotic analgesics have failed and as preanesthetic medication;
         also used to relieve dyspnea of acute left ventricular failure and pulmonary edema and pain of MI.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to opiates; increased intracranial pressure; convulsive disorders; acute alcoholism; acute bronchial asthma,
         chronic pulmonary diseases, severe respiratory depression; chemical-irritant induced pulmonary edema; prostatic hypertrophy;
         diarrhea caused by poisoning until the toxic material has been eliminated; undiagnosed acute abdominal conditions; following
         biliary tract surgery and surgical anastomosis; pancreatitis; acute ulcerative colitis; severe liver or renal insufficiency;
         Addison's disease; hypothyroidism; during labor for delivery of a premature infant, in premature infants; pregnancy (category
         B; D in long-term use or when high dose is used); lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Toxic psychosis; cardiac arrhythmias, cardiovascular disease; emphysema; kyphoscoliosis; cor pulmonale; severe obesity; reduced
         blood volume; very old, very young, or debilitated patients; labor.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Pain Relief</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1030 mg q4h prn or 1530 mg sustained release q812h; <b>(Kadian)</b> dose q1224h, increase dose prn for pain relief; <b>(Avinza)</b> dose q24h <span class="rdroute">IV</span> 2.515 mg q4h or 0.810 mg/h by continuous infusion, may increase prn to control pain or 510 mg given epidurally
               q24h <span class="rdroute">Epidural</span> (<b>DepoDur</b> only) 1015 mg as single dose 30 min before surgery (max: 20 mg) <span class="rdroute">IM/SC</span> 520 mg q4h <span class="rdroute">PR</span> 1020 mg q4h prn<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> 0.050.1 mg/kg q4h or 0.0252.6 mg/kg/h by continuous infusion <span class="rdroute">IM/SC</span> 0.10.2 mg/kg q4h (max: 15 mg/dose) <span class="rdroute">PO</span> 0.20.5 mg/kg q46h; 0.30.6 mg/kg sustained release q12h<br/><span class="rdage">Neonate:</span> <span class="rdroute">IV/IM/SC</span> 0.05 mg/kg q48h (max: 0.1 mg/kg) or 0.010.02 mg/kg/h<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Use a fixed, individualized schedule when narcotic analgesic therapy is started to provide effective management; blood levels
            can be maintained and peaks of pain can be prevented (usually a 4-h interval is adequate).
         </li>
<li>Use lower dosage for older adult or debilitated patients than for adults.</li>
<li>Do not break in half, crush, or allow sustained release tablet to be chewed.</li>
<li>Do not give patient sustained release tablet within 24 h of surgery.</li>
<li>Dilute oral solution in approximately 30 mL or more of fluid or semisolid food. A calibrated dropper comes with the bottle.
            Read labels carefully when using liquid preparation; available solutions: 20 mg/mL; 100 mg/mL.
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>
                     					Note: Verify correct IV concentration and rate of infusion/injection for administration to neonates, infants, or children with physician.
                     				
                  </li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Dilute 210 mg in at least 5 mL of sterile water for injection.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give a single dose over 45 min. Avoid rapid administration.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<b>Aminophylline,</b>
<b>amobarbital,</b>
<b>chlorothiazide,</b>
<b>floxacillin,</b>
<b>fluorouracil,</b>
<b>haloperidol,</b>
<b>heparin,</b>
<b>meperidine,</b>
<b>pentobarbital,</b>
<b>phenobarbital,</b>
<b>phenytoin,</b>
<b>sodium bicarbonate,</b>
<b>thiopental.</b>
<span class="incompattype">Y-site:</span>
<b>Amphotericin B cholesteryl complex,</b>
<b>azithromycin, cefepime,</b>
<b>doxorubicin liposome,</b>
<b>minocycline,</b>
<b>sargramostim,</b>
<b>tetracycline.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store at 15°30° C (59°86° F). Avoid freezing. Refrigerate suppositories. Protect all formulations
            from light.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Hypersensitivity [<span class="speceff-common">Pruritus,</span> rash, urticaria, edema, hemorrhagic urticaria (rare), <span class="speceff-life">anaphylactoid reaction</span> (rare)], sweating, skeletal muscle flaccidity; cold, clammy skin, hypothermia. <span class="typehead">CNS:</span> Euphoria, insomnia, disorientation, visual disturbances, dysphoria, paradoxic CNS stimulation (restlessness, tremor, delirium,
      insomnia), convulsions (infants and children); decreased cough reflex, drowsiness, dizziness, deep sleep, coma, continuous
      intrathecal infusion may cause granulomas leading to paralysis.  <span class="typehead">Special Senses:</span> Miosis. <span class="typehead">CV:</span> Bradycardia, palpitations, syncope; flushing of face, neck, and upper thorax; orthostatic hypotension, <span class="speceff-life">cardiac arrest</span>. <span class="typehead">GI:</span>
<span class="speceff-common">Constipation,</span> anorexia, dry mouth, biliary colic, <span class="speceff-common">nausea,</span> vomiting, elevated transaminase levels. <span class="typehead">Urogenital:</span> Urinary retention or urgency, dysuria, oliguria, reduced libido or potency (prolonged use). <span class="typehead">Other:</span> Prolonged labor and respiratory depression of newborn. <span class="typehead">Hematologic:</span> Precipitation of porphyria. <span class="typehead">Respiratory:</span>
<span class="speceff-life">Severe respiratory depression</span> (as low as 24/min) or <span class="speceff-life">arrest</span>; pulmonary edema. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>False-positive <span class="alt">urine glucose</span> determinations may occur using <span class="alt">Benedict's solution.</span>
<span class="alt">Plasma amylase</span> and <span class="alt">lipase</span> determinations may be falsely positive for 24 h after use of morphine; <span class="alt">transaminase levels</span> may be elevated.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">cns depressants</span>, <span class="classification">sedatives</span>, <span class="classification">barbiturates</span>, <span class="classification">benzodiazepines</span>, and <span class="classification">tricyclic antidepressants</span> potentiate CNS depressant effects. Use <span class="classification">mao inhibitors</span> cautiously; they may precipitate hypertensive crisis. <span class="classification">phenothiazines</span> may antagonize analgesia. Use with <b>alcohol</b> may lead to potentially fatal overdoses. <span class="typehead">Herbal:</span>
<b>Kava-kava, valerian, St. John's wort</b> may increase sedation. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Variably absorbed from GI tract. <span class="typehead">Peak:</span> 60 min PO; 2060 min PR; 5090 min SC; 3060 min IM; 20 min IV. <span class="typehead">Duration:</span> Up to 7 h. <span class="typehead">Distribution:</span> Crosses bloodbrain barrier and placenta; distributed in breast milk. <span class="typehead">Metabolism:</span> Metabolized primarily in liver. <span class="typehead">Elimination:</span> 90% of drug and metabolites excreted in urine in 24 h; 710% excreted in bile. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Obtain baseline respiratory rate, depth, and rhythm and size of pupils before administering the drug. Respirations of 12/min
            or below and miosis are signs of toxicity. Withhold drug and report to physician.
         </li>
<li>Observe patient closely to be certain pain relief is achieved. Record relief of pain and duration of analgesia.</li>
<li>Be alert to elevated pulse or respiratory rate, restlessness, anorexia, or drawn facial expression that may indicate need
            for analgesia.
         </li>
<li>Differentiate among restlessness as a sign of pain and the need for medication, restlessness associated with hypoxia, and
            restlessness caused by morphine-induced CNS stimulation (a paradoxic reaction that is particularly common in women and older
            adult patients).
         </li>
<li>Monitor for respiratory depression; it can be severe for as long as 24 h after epidural or intrathecal administration.</li>
<li>Monitor carefully those at risk for severe respiratory depression after epidural or intrathecal injection: Older adult or
            debilitated patients or those with decreased respiratory reserve (e.g., emphysema, severe obesity, kyphoscoliosis).
         </li>
<li>Continue monitoring for respiratory depression for at least 24 h after each epidural or intrathecal dose.</li>
<li>Assess vital signs at regular intervals. Morphine-induced respiratory depression may occur even with small doses, and it increases
            progressively with higher doses (generally max: 90 min after SC, 30 min after IM, and 7 min after IV).
         </li>
<li>Encourage changes in position, deep breathing, and coughing (unless contraindicated) at regularly scheduled intervals. Narcotic
            analgesics also depress cough and sigh reflexes and thus may induce atelectasis, especially in postoperative patients.
         </li>
<li>Be alert for nausea and orthostatic hypotension (with light-headedness and dizziness) in ambulatory patients or when a supine
            patient assumes the head-up position or in patients not experiencing severe pain.
         </li>
<li>Monitor I&amp;O ratio and pattern. Report oliguria or urinary retention. Morphine may dull perception of bladder stimuli; therefore,
            encourage the patient to void at least q4h. Palpate lower abdomen to detect bladder distention.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Avoid alcohol and other CNS depressants while receiving morphine.</li>
<li>Do not use of any OTC drug unless approved by physician.</li>
<li>Do not smoke or ambulate without assistance after receiving drug. Bedside rails are advised.</li>
<li>Use caution or avoid tasks requiring alertness (e.g., driving a car) until response to drug is known since morphine may cause
            drowsiness, dizziness, or blurred vision.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>